European Journal of Clinical Investigation,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 2, 2024
Abstract
Background
Severe
tricuspid
regurgitation
(TR)
is
associated
with
high
morbidity
and
mortality.
Isolated
TR,
defined
as
TR
without
overt
heart
disease,
typical
offers
limited
cardiac
treatment
options
other
than
interventional
repair
or
replacement.
Survival
history
of
cancer
active
may
lead
to
an
unnecessary
delay
treatment.
Methods
We
included
all
patients
diagnosed
severe
at
the
Medical
University
Vienna
between
2003
2016
who
had
normal
left
ventricular
function
no
valvular
lesions.
Outcome
analysis
was
performed
on
type,
status
number
organs
affected
by
cancer.
Results
A
total
973
were
included.
182
(19%)
cancer,
52
130
a
time
diagnosis.
Oncologic
divided
into
subgroups
gastrointestinal,
skin,
glands,
gynaecological,
breast,
urogenital,
lung
cancers.
Ten‐year
mortality
higher
those
(
p
<
0.001).
Multivariate
adjusting
for
age
did
not
reveal
significantly
in
compared
=
0.59).
Patients
lung,
active,
multi‐organ
showed
highest
Conclusions
Mortality
isolated
increased
but
These
should
be
discussed
interdisciplinary
cardio‐oncology
teams
avoid
delaying
life‐saving
JCO Oncology Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 6, 2025
The
management
of
renal
cell
carcinoma
(RCC)
has
seen
significant
advancements
in
recent
years
with
the
introduction
novel
therapeutic
agents
and
combination
regimens.
Immune
checkpoint
inhibitors
(ICIs)
have
revolutionized
treatment
landscape,
particularly
for
advanced
metastatic
RCC,
where
ICI-based
combinations
shown
substantial
improvements
survival
outcomes.
Dual
immunotherapy
combinations,
such
as
nivolumab
plus
ipilimumab,
ICI-vascular
endothelial
growth
factor
(VEGF)
tyrosine
kinase
inhibitor
(TKI)
including
pembrolizumab
axitinib,
cabozantinib,
lenvatinib,
demonstrated
overall
(OS)
benefits
first-line
treatment,
redefining
standard
care
RCC.
Adjuvant
is
also
approved
resected
high-risk
RCC
only
adjuvant
therapy
that
prolongs
OS
Additionally,
development
belzutifan,
a
hypoxia-inducible
factor-2
alpha
inhibitor,
offers
new
option
patients
whose
disease
progresses
after
ICI
VEGF
TKI
therapies.
Recent
results
from
CONTACT-3
TiNiVo-2
confirm
rechallenge
should
be
generally
discouraged.
This
review
provides
detailed
overview
current
evidence
supporting
immune-based
well
insights
into
sequencing
strategies
Circulation Research,
Journal Year:
2024,
Volume and Issue:
135(12), P. 1161 - 1174
Published: Oct. 28, 2024
BACKGROUND:
Given
the
growing
acknowledgment
of
detrimental
effects
excessive
myocardial
fibrosis
on
pathological
remodeling
after
ischemia-reperfusion
injury
(I/R),
targeting
modulation
may
offer
protective
and
therapeutic
advantages.
However,
effective
clinical
interventions
therapies
that
target
remain
limited.
As
a
promising
chimeric
antigen
receptor
(CAR)
cell
therapy,
whether
CAR
macrophages
(CAR-Ms)
can
be
used
to
treat
I/R
remains
unclear.
METHODS:
The
expression
FAP
(fibroblast
activation
protein)
was
studied
in
mouse
hearts
I/R.
CAR-Ms
were
generated
FAP-expressing
cardiac
fibroblasts
phagocytosis
activity
tested
vitro.
efficacy
safety
treating
evaluated
vivo.
RESULTS:
significantly
upregulated
activated
as
early
3
days
Upon
demonstrating
their
ability
engulf
FAP-overexpressing
fibroblasts,
we
intravenously
administered
mice
at
found
improved
function
reduced
No
toxicities
associated
with
detected
heart
or
other
organs
2
weeks
Finally,
conferred
long-term
cardioprotection
against
CONCLUSIONS:
Our
proof-of-concept
study
demonstrates
potential
alleviating
potentially
opens
new
avenues
for
treatment
range
diseases
include
fibrotic
phenotype.
ACTA HISTOCHEMICA ET CYTOCHEMICA,
Journal Year:
2025,
Volume and Issue:
58(1), P. 1 - 8
Published: Feb. 6, 2025
Immune
tolerance
is
essential
for
safeguarding
the
body's
own
tissues
from
immune
system
attacks.
During
pregnancy,
maternal
tolerates
semi-allogeneic
fetus
through
mechanisms
such
as
placental
programmed
cell
death
1
(PD-1)-ligand
(PD-L1)
expression,
regulatory
T
cells
(Tregs),
cytokine
modulation,
and
hormonal
changes.
Placental
PD-L1
particularly
important
in
suppressing
responses
preventing
fetal
rejection.
Following
delivery,
loss
of
PD-L1-rich
placenta
can
destabilize
tolerance,
potentially
leading
to
postpartum
autoimmune
diseases
fulminant
type
diabetes,
characterized
by
rapid
insulin
depletion
severe
hyperglycemia.
Similarly,
checkpoint
inhibitors
(ICIs),
widely
used
cancer
immunotherapy,
block
checkpoints
like
PD-1
enhance
antitumor
immunity
disrupting
immunotolerance
tumors.
However,
this
mechanism
sometimes
result
immune-related
adverse
events
(irAEs),
including
diabetes.
Given
critical
role
HLA
haplotypes
environmental
factors
development
conditions,
identifying
shared
among
individuals
patients
undergoing
ICI
therapy
who
experience
abnormalities
could
provide
valuable
insights.
Such
understanding
may
improve
strategies
managing
associated
with
both
changes
treatments.
Frontiers in Cardiovascular Medicine,
Journal Year:
2025,
Volume and Issue:
12
Published: Feb. 14, 2025
Recent
advances
in
immunotherapy
have
significantly
improved
outcomes
for
cancer
patients.
However,
therapies
such
as
immune
checkpoint
inhibitors
(ICIs)
can
lead
to
immune-related
adverse
events,
including
potentially
fatal
ICI-myocarditis.
The
diagnosis
of
ICI-myocarditis
is
complex,
and
cardiac
MRI
plays
a
crucial
role
identifying
this
condition.
This
report
presents
novel
finding
elevated
muscular
T1
T2
relaxation
parameters
using
standard
CMR
sequences,
correlating
with
the
clinical
progression
ICI-myotoxicity
affecting
not
only
heart
but
also
skeletal
thoracic
muscles
diaphragm.
Identifying
diaphragm
involvement
these
patients
particularly
important,
it
may
result
respiratory
failure.
has
shown
significant
potential
assessing
diaphragmatic
function,
well
detecting
tissue
damage
edema,
while
monitoring
their
evolution
over
time.
comprehensive,
imaging-based
approach
could
guide
treatment
decisions,
use
corticosteroids
immunosuppressive
therapies.
Combining
functional
non-invasive
assessments
single
examination
enhance
early
improve
management
undergoing
ICI
therapy.
